AUTHORS
Lori E Crosby, PsyD, Aimee Kim Hildenbrand, PhD2, Charles T Quinn, MD, MS3, Soumitri Sil, PhD ABPP4, Carlton Dampier, MD5, Alexis A. Thompson, MD MPH6, Lisa A. Schwartz, PhD7, Constance Mara8, Stephanie Guarino, MD MSHP9, Taylor Richardson10, Elysia Smith, CHES11, Naomi Joffe, PhD12, Margaret Brock, PhD13, Emily McTate, PhD, LP14, Avani Modi, PhD15
AFFILIATIONS
1 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
2 Nemours Children's Health, wilmington, Delaware, United States
3 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
4 Aflac Cancer & Blood Disorders Center - Hughes Spalding Hospital, Atlanta, Georgia, United States
5 Aflac Cancer & Blood Disorders Center - Hughes Spalding Hospital, Atlanta, Georgia, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
9 Nemours Children's Health, wilmington, Delaware, United States
10 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
11 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
12 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
13 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Cincinnati Children's Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
ABSTRACT
Background:
Sickle cell disease (SCD) is the most common life-shortening genetic disorder in the United States. Adolescence and young adulthood are critical developmental periods during which disease-related complications increase and responsibility for self-management shifts from caregivers to youth. Healthcare access challenges, illness-related stigma, negative healthcare experiences, and financial hardship can hinder effective self-management and contribute to poorer health outcomes. SCThrive was developed as a theory-driven, culturally tailored eHealth intervention to improve patient activation, or the knowledge, skills, and self-efficacy necessary for managing SCD, while simultaneously addressing barriers to disease management. Pilot data demonstrated improvements in patient activation and self-management behaviors among adolescents and young adults (AYA) with SCD, supporting further evaluation in a multicenter randomized controlled trial (RCT).
Aims:
This ongoing multicenter RCT (NCT06290401) evaluates the efficacy of SCThrive versus enhanced standard care on patient activation. Secondary objectives are to assess the effects of SCThrive on self-management behaviors, functional disability, health-related quality of life (HRQOL), healthcare utilization, and the relationship between barriers to care and treatment response. It is hypothesized that participants randomized to SCThrive will demonstrate greater improvements in patient activation than those receiving enhanced standard care.
Methods:
This pragmatic, parallel-group RCT is being conducted across four pediatric SCD centers in the United States. Eligible participants are AYA aged 13-21 years with confirmed SCD receiving care at a participating center. Exclusion criteria include another chronic medical condition that could affect patient activation assessment, inability to complete study procedures in English, or cognitive/psychiatric impairment that would interfere with participation. Participants are randomized 1:1 to SCThrive or SCHealthED (enhanced standard care) using age-stratified block randomization (13-17 vs. 18-21 years).
SCThrive consists of therapist-facilitated virtual group self-management sessions and a companion mobile application that includes engagement strategies, assessment of self-management barriers, and individualized support. Outcomes are assessed at baseline, post-treatment, and 3-month follow-up. The primary outcome is patient activation (PAM-13). Secondary outcomes include self-management behaviors, functional disability, HRQOL, and emergency department utilization.
Analyses will follow the intention-to-treat principle. Longitudinal treatment effects will be evaluated using mixed-effects models to account for repeated assessments across baseline, post-treatment, and 3-month follow-up. Models will include treatment group, time, and treatment-by-time interaction effects, with adjustment for stratification variables and site. Count outcomes, including emergency department utilization, will be analyzed using generalized linear mixed models appropriate for count data. Exploratory analyses will evaluate associations between sociodemographic factors and intervention responsiveness.
Trial Status:
The study is actively enrolling and conducting follow-up assessments. To date, 150 AYA have been enrolled; most were female (53%), aged 13 to 17 years (61.3%), identified as Black/African American (99.3%), and had HbSS or HbSβ⁰-thalassemia genotypes (59.7%).
Discussion:
This study addresses a critical gap by integrating evidence-based self-management support with a comprehensive approach to barriers. If efficacious, SCThrive may provide a scalable, technology-enabled model for improving patient activation, self-management, and health outcomes among youth with SCD.
DISCLOSURES
Lori E Crosby, PsyD: Pfizer - Honoraria